Valrubicin , 98% , 56124-62-0
CAS NO.：56124-62-0
Empirical Formula: C34H36F3NO13
Molecular Weight: 723.64
MDL number: MFCD01939322
EINECS: 680-664-1
| Pack Size | Price | Stock | Quantity |
| 25mg | RMB612.00 | In Stock |
|
| 50mg | RMB1039.20 | In Stock |
|
| 100mg | RMB1765.60 | In Stock |
|
| 250mg | RMB3000.80 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 116-117 °C |
| Boiling point: | 135-136 C |
| Density | 1.3473 (estimate) |
| storage temp. | 2-8°C |
| solubility | DMSO (Slightly), Methanol (Slightly) |
| form | Solid |
| pka | 7.34±0.60(Predicted) |
| color | Red |
| Water Solubility | insoluble |
| InChIKey | ZOCKGBMQLCSHFP-XGMQQLFPNA-N |
| SMILES | C12=C(O)C3=C(C(=O)C4C=CC=C(OC)C=4C3=O)C(O)=C1C[C@@](O)(C(=O)COC(=O)CCCC)C[C@@H]2O[C@@H]1O[C@H]([C@@H](O)[C@@H](NC(=O)C(F)(F)F)C1)C |&1:21,34,36,38,39,41,r| |
Description and Uses
Valrubicin was launched as a new 'chemotherapeutic agent for the treatment of bladder cancer, particularly in patients with BCG-refractory carcinoma in situ (CIS) of the bladder for whom immediate cystectomy is unacceptable. It belongs to the class of anthracyclines, the widest used in human cancers, and is a N-trifluoroacetyl 14-valerate derivative of doxorubicin.Valrubicin can be obtained in 3 steps from daunomycin by N-trifluoroacetylation of the sugar moiety then iodination of the 2-acetyl group and introduction of a valerate residue. A proposed mechanism involved in the cytotoxicity of Valrubicin coud be the blockade of SV40 large T antigen helicase; this cellular enzyme is involved in the formation of a ternary complex with DNA to maintain the topographic structure of DNA during transcription. In patients with CIS of bladder refractory to front line and second line therapies, intravesical instillation of Valrubicin resulted in a complete response with a significant rate and allowed a delay in cystectomy. Systemic absorption was minimal and accordingly produced a lower incidence of cardiotoxicity compared with doxorubicin.
Chemotherapy drug used to treat cancer of the bladder.
Safety
| Symbol(GHS) |   GHS08,GHS06 |
| Signal word | Danger |
| Hazard statements | H351-H340-H312-H332-H360-H301 |
| Precautionary statements | P201-P202-P281-P308+P313-P405-P501-P264-P270-P301+P310-P321-P330-P405-P501-P261-P271-P304+P340-P312-P280-P302+P352-P312-P322-P363-P501 |
| Hazard Codes | Xi |
| Risk Statements | 36/37/38 |
| Safety Statements | 26-37/39 |
| HS Code | 2941906000 |
| Hazardous Substances Data | 56124-62-0(Hazardous Substances Data) |
| Toxicity | dnd-hmn:lym 3 mg/L CJBIAE 58,720,80 |
